ðŸ§
Clinical Trial Compass
Am I eligible?
Pricing
About
Sign in
Back to search
Expanded Access Use of Cemiplimab in Patients With Solid Tumors (NCT06132191) | Clinical Trial Compass
APPROVED_FOR_MARKETING
Not Applicable
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
Plain-language summary
Provide expanded access of cemiplimab in patients with solid tumors
Trial details
NCT ID
NCT06132191
Sponsor
Regeneron Pharmaceuticals
Sponsor type
INDUSTRY
Study type
EXPANDED_ACCESS
View on ClinicalTrials.gov
More Non-Small Cell Lung Cancer (NSCLC) trials